Enhanced Anti-Tumor Effects by Combination of Tucatinib and Radiation in HER2-Overexpressing Human Cancer Cell Lines
L Amrell, E Bär, A Glasow, RD Kortmann, C Seidel… - 2024 - researchsquare.com
Background Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …
Enhanced Anti-Tumor Effects by Combination of Tucatinib and Radiation in HER2-Overexpressing Human Cancer Cell Lines
L Amrell, E Bär, A Glasow, R Kortmann, C Seidel… - 2024 - europepmc.org
Background: Tucatinib (TUC), a HER2-directed tyrosine kinase inhibitor, is the first targeted
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …
drug demonstrating intracranial efficacy and significantly prolonged survival in metastatic …